Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the successful completion of its acquisition of MGI PHARMA, INC...
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the completion of the offer by its indirect wholly-owned...
NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded...
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the satisfaction of all of the conditions to the offer by its...
MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study results published in the February issue of the Journal...
Eisai Co., Ltd. (Tokyo, TSE: 4523) (?Eisai?) and MGI PHARMA, INC. (NASDAQ: MOGN) (?MGI PHARMA?) announced today that the Federal Trade Commission has granted early termination...
NEW YORK, Jan. 16 /PRNewswire/ -- HMS Holdings Corp. (NASDAQ:HMSY) will replace MGI PHARMA Inc. (NASDAQ:MOGN) in the S&P SmallCap 600 after the close of trading on Tuesday, January 22. MOGN is...
On December 26, 2007, MGI PHARMA, INC. issued a Notice of Conversion Right to holders of its Senior Subordinated Convertible Notes due 2024. The notice incorrectly listed...
MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical...
MGI PHARMA, INC. (NASDAQ:MOGN) (the ?Company? or ?MGI PHARMA?), today announced that the Company?s Senior Subordinated Convertible Notes due 2024 (the ?Notes?) shall become...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
